Fresenius SE & Co KGaA Hits New 52-Week High Amid Strong Growth Prospects
Fresenius SE & Co KGaA has reached a new 52-week high, with analysts predicting a 5% organic revenue growth and promising prospects for 2025.
2 minutes to read
Fresenius SE Stock Stabilizes Near Year-High with Strong Sector Outperformance
Fresenius SE & Co KGaA’s stock price has stabilized near its year-high, with a 17.83% gain since the start of the year, and technical indicators suggesting potential for further upside.
One minute to read
Fresenius SE Stock Soars 10% Amid Sales Growth, FDA Approval, and Dividend Announcement
Fresenius SE’s stock price has increased by nearly 10% over the past four weeks, driven by improved sales, earnings margins, and reduced debt, as well as recent FDA approval for its denosumab biosimilars.
One minute to read
Fresenius Reduces Stake in Fresenius Medical Care to Boost Financial Flexibility Amid Market Volatility
Fresenius SE & Co KGaA plans to reduce its stake in Fresenius Medical Care AG from 32.2% to 25% plus one share, a move expected to provide the company with financial flexibility and navigate market volatility.
2 minutes to read